Cargando…
Measurement of serum total and free prostate-specific antigen in women with colorectal carcinoma
We investigated the diagnostic value and the relationship with clinicopathological features of total and free prostate-specific antigen by measuring the concentrations of these markers in the sera of 75 women with colorectal carcinoma and in 30 healthy women. Measurements were performed by immunorad...
Autores principales: | , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2002
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2375183/ https://www.ncbi.nlm.nih.gov/pubmed/11870506 http://dx.doi.org/10.1038/sj.bjc.6600049 |
_version_ | 1782154596552015872 |
---|---|
author | Duraker, N Can, D Parıltı, M |
author_facet | Duraker, N Can, D Parıltı, M |
author_sort | Duraker, N |
collection | PubMed |
description | We investigated the diagnostic value and the relationship with clinicopathological features of total and free prostate-specific antigen by measuring the concentrations of these markers in the sera of 75 women with colorectal carcinoma and in 30 healthy women. Measurements were performed by immunoradiometric assay which utilizes monoclonal and polyclonal anti-prostate-specific antigen antibodies; the lowest detection level for both markers was 0.01 ng ml(−1). Free prostate-specific antigen levels were significantly higher in women with colorectal carcinoma than healthy women (P=0.006). The percentage of free prostate-specific antigen predominant (free prostate-specific antigen/total prostate-specific antigen >50%) subjects was 20% in colorectal carcinoma patients and 3.3% in healthy women (P=0.035). Cut-off values were 0.34 ng ml(−1) for total prostate-specific antigen and 0.01 ng ml(−1) for free prostate-specific antigen. In women with colorectal carcinoma, total prostate-specific antigen positivity was 20% and free prostate-specific antigen positivity was 34.6%. When compared to negatives, total prostate-specific antigen positive patients had a lower percentage of well-differentiated (P=0.056) and early stage (stages I and II) tumours (P=0.070). However, patients with predominant free prostate-specific antigen, had a higher percentage of well-differentiated (P=0.014) and early stage tumours (P=0.090) than patients with predominant bound prostate-specific antigen. In conclusion, although the sensitivity of free prostate-specific antigen predominancy is low (20%), in distinguishing women with colorectal carcinoma than healthy women, its specificity is high (96.7%). Free prostate-specific antigen predominancy tends to be present in less aggressive tumours. These findings may indicate clinical significance of preoperative measurement of serum total and free prostate-specific antigen in women with colorectal carcinoma. British Journal of Cancer (2002) 86, 203–206. DOI: 10.1038/sj/bjc/6600049 www.bjcancer.com © 2002 The Cancer Research Campaign |
format | Text |
id | pubmed-2375183 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2002 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-23751832009-09-10 Measurement of serum total and free prostate-specific antigen in women with colorectal carcinoma Duraker, N Can, D Parıltı, M Br J Cancer Clinical We investigated the diagnostic value and the relationship with clinicopathological features of total and free prostate-specific antigen by measuring the concentrations of these markers in the sera of 75 women with colorectal carcinoma and in 30 healthy women. Measurements were performed by immunoradiometric assay which utilizes monoclonal and polyclonal anti-prostate-specific antigen antibodies; the lowest detection level for both markers was 0.01 ng ml(−1). Free prostate-specific antigen levels were significantly higher in women with colorectal carcinoma than healthy women (P=0.006). The percentage of free prostate-specific antigen predominant (free prostate-specific antigen/total prostate-specific antigen >50%) subjects was 20% in colorectal carcinoma patients and 3.3% in healthy women (P=0.035). Cut-off values were 0.34 ng ml(−1) for total prostate-specific antigen and 0.01 ng ml(−1) for free prostate-specific antigen. In women with colorectal carcinoma, total prostate-specific antigen positivity was 20% and free prostate-specific antigen positivity was 34.6%. When compared to negatives, total prostate-specific antigen positive patients had a lower percentage of well-differentiated (P=0.056) and early stage (stages I and II) tumours (P=0.070). However, patients with predominant free prostate-specific antigen, had a higher percentage of well-differentiated (P=0.014) and early stage tumours (P=0.090) than patients with predominant bound prostate-specific antigen. In conclusion, although the sensitivity of free prostate-specific antigen predominancy is low (20%), in distinguishing women with colorectal carcinoma than healthy women, its specificity is high (96.7%). Free prostate-specific antigen predominancy tends to be present in less aggressive tumours. These findings may indicate clinical significance of preoperative measurement of serum total and free prostate-specific antigen in women with colorectal carcinoma. British Journal of Cancer (2002) 86, 203–206. DOI: 10.1038/sj/bjc/6600049 www.bjcancer.com © 2002 The Cancer Research Campaign Nature Publishing Group 2002-01-21 /pmc/articles/PMC2375183/ /pubmed/11870506 http://dx.doi.org/10.1038/sj.bjc.6600049 Text en Copyright © 2002 The Cancer Research Campaign https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Clinical Duraker, N Can, D Parıltı, M Measurement of serum total and free prostate-specific antigen in women with colorectal carcinoma |
title | Measurement of serum total and free prostate-specific antigen in women with colorectal carcinoma |
title_full | Measurement of serum total and free prostate-specific antigen in women with colorectal carcinoma |
title_fullStr | Measurement of serum total and free prostate-specific antigen in women with colorectal carcinoma |
title_full_unstemmed | Measurement of serum total and free prostate-specific antigen in women with colorectal carcinoma |
title_short | Measurement of serum total and free prostate-specific antigen in women with colorectal carcinoma |
title_sort | measurement of serum total and free prostate-specific antigen in women with colorectal carcinoma |
topic | Clinical |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2375183/ https://www.ncbi.nlm.nih.gov/pubmed/11870506 http://dx.doi.org/10.1038/sj.bjc.6600049 |
work_keys_str_mv | AT durakern measurementofserumtotalandfreeprostatespecificantigeninwomenwithcolorectalcarcinoma AT cand measurementofserumtotalandfreeprostatespecificantigeninwomenwithcolorectalcarcinoma AT parıltım measurementofserumtotalandfreeprostatespecificantigeninwomenwithcolorectalcarcinoma |